Vaccine Analysis: Strategies, Principles, and Control

Brian K. Nunnally

ISBN 10: 3662450232 / ISBN 13: 9783662450239

Published by Springer, 2014

About this Item

Druck auf Anfrage Neuware - Printed after ordering - This book is an indispensable tool for anyone involved in the research, development, or manufacture of new or existing vaccines. It describes a wide array of analytical and quality control technologies for the diverse vaccine modalities.Topics covered include the application of both classical and modern bio-analytical tools; procedures to assure safety and control of cross contamination; consistent biological transition of vaccines from the research laboratory to manufacturing scale; whole infectious attenuated organisms, such as live-attenuated and inactivated whole-cell bacterial vaccines and antiviral vaccines using attenuated or inactivated viruses; principles of viral inactivation and the application of these principles to vaccine development; recombinant DNA approaches to produce modern prophylactic vaccines; bacterial subunit, polysaccharide and glycoconjugate vaccines; combination vaccines that contain multiple antigens as well as regulatory requirements and the hurdles of licensure.

Seller Inventory # 9783662450239

Bibliographic Details

• Title: Vaccine Analysis: Strategies, Principles, and Control
• Publisher: Springer
• Publication Date: 2014
• Language: English
• ISBN 10: 3662450232
• ISBN 13: 9783662450239
• Binding: Buch
• Condition: Neu
• Dimensions: 241W x 160H x 42D millimeters 241 millimeters width by 160 millimeters height by 42 millimeters depth
• Weight: 1174 grams

About this title

Synopsis

This book is an indispensable tool for anyone involved in the research, development, or manufacture of new or existing vaccines. It describes a wide array of analytical and quality control technologies for the diverse vaccine modalities.

Topics covered include the application of both classical and modern bio-analytical tools; procedures to assure safety and control of cross contamination; consistent biological transition of vaccines from the research laboratory to manufacturing scale; whole infectious attenuated organisms, such as live-attenuated and inactivated whole-cell bacterial vaccines and antiviral vaccines using attenuated or inactivated viruses; principles of viral inactivation and the application of these principles to vaccine development; recombinant DNA approaches to produce modern prophylactic vaccines; bacterial subunit, polysaccharide and glycoconjugate vaccines; combination vaccines that contain multiple antigens as well as regulatory requirements and the hurdles of licensure.